Abstract: Objective: To observe the tolerability of Chinese melanoma patients to four-week high-dose interferon alfa- 2b (INTRON A®, Schering-Plough) therapy. Methods:A total of29patients with high risk melanoma American Joint Committee on Cancer Staging (AJCC) IIB-IIIC who received adjuvant interferon therapy in our hospital between September 2007 and May 2009 were retrospectively reviewed. Patients received 4 hours of intravenous infusion of interferon alfa- 2b dose range, 22.00million international unit (MIU) to33.75MIU IV5 days/week for4 weeks. The adverse events were evaluated with National Cancer Institute Common Toxicity Criteria (NCI 2.0 version). Results: The average daily dose was 17.63MIU/(m2·d). The therapy was ended in two patients because of poor wound healing or intolerability to severe fatigue. The most common adverse events were myelosuppression. Grade 3/4 neutropenia was observed in69% (20/29) patients and was rapidly reversed after conventional support interventions. Grade 1/2 abnormal hepatic function occurred in 18 cases (62% ). Twenty six patients were followed up for 3 to 22 months. Five patients developed early progression: one with local recurrence, two with regional lymph node metastasis, one with in-transit metastasis in the affected limb, and one with distant metastasis.Conclusion:High-dose interferon alfa-2b regimen can be well tolerated by Chinese patients but cannot effectively inhibit subclinical lesions.